Auranofin + Sirolimus for Ovarian Cancer
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial is testing auranofin and sirolimus in patients with metastatic serous ovarian cancer. These drugs might help control the cancer and improve blood cell counts. Auranofin is being tested for its feasibility in treating ovarian cancer patients without symptoms.
Who Is on the Research Team?
Aminah Jatoi, M.D.
Principal Investigator
Mayo Clinic
Are You a Good Fit for This Trial?
This trial is for people with ovarian cancer, including serous cystadenoma, who have measurable disease and a life expectancy of at least 12 weeks. They should be relatively healthy (ECOG score 0 or 1) and have certain blood counts and chemistries within specific ranges. Those with controlled brain metastasis, unresolved effects from past treatments, or sensitive to platinum-based therapies are excluded.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive auranofin and sirolimus orally once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Follow-up
Participants are monitored for safety and effectiveness after treatment completion every 6 months for 3 years.
What Are the Treatments Tested in This Trial?
Interventions
- Auranofin
- Sirolimus
Find a Clinic Near You
Who Is Running the Clinical Trial?
Mayo Clinic
Lead Sponsor
National Cancer Institute (NCI)
Collaborator